Bispectral Index (BIS) for Classification of Procalcitonin (PCT) Sepsis Grades in Critically Ill Patients With Sepsis
Launched by SUEZ CANAL UNIVERSITY · Aug 8, 2017
Trial Information
Current as of May 11, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a tool called the Bispectral Index (BIS) can help doctors understand the level of mental state in critically ill patients with sepsis, a serious infection that can lead to organ failure. The goal is to see if BIS can effectively show how severe the sepsis is based on another marker called procalcitonin (PCT), and to help monitor whether a patient is getting better or worse.
To be part of this study, patients must be diagnosed with sepsis, and they should not have taken any medications that could affect BIS monitoring. If eligible, participants can expect to have their BIS levels monitored alongside their treatment for sepsis. This research is important as it could improve how doctors assess and manage sepsis, ultimately leading to better care for patients. The trial is currently recruiting participants of all ages and genders.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: patients with sepsis
- • patients with sepsis
- Exclusion Criteria:
- • Patients who received drugs that would interfere with BIS monitoring
About Suez Canal University
Suez Canal University is a distinguished academic institution dedicated to advancing medical research and education in the region. As a clinical trial sponsor, the university focuses on conducting innovative studies that aim to enhance patient care and outcomes. Leveraging its strong network of healthcare professionals and state-of-the-art facilities, Suez Canal University fosters collaboration between researchers and clinicians to explore new therapeutic approaches and validate clinical practices. Committed to ethical standards and scientific rigor, the university plays a pivotal role in contributing to the global body of medical knowledge and improving healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dalian, Dalian, China
Patients applied
Trial Officials
Ashraf Dahaba, MD, MSc
Principal Investigator
Suez Canal University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials